{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141841,"version":"4.3.3"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Cempra, Inc"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, nonspecific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia. This study reports the potent\n in vitro<\/jats:italic>\n activity of solithromycin against a collection of recent isolates of\n Bordetella pertussis<\/jats:named-content>\n .\n <\/jats:p>","DOI":"10.1128\/aac.01271-16","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T01:59:02Z","timestamp":1473731942000},"page":"7043-7045","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["In Vitro<\/i>\n Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen"],"prefix":"10.1128","volume":"60","author":[{"given":"Dwight J.","family":"Hardy","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vicino","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Cempra, Inc., Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.341.6145.454"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1209369"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00117-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05658-11"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04568-14"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3147"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819e3f7a"},{"key":"e_1_3_2_9_2","volume-title":"Azithromycin (Zithromax or Zmax): drug safety communication\u2014risk of potentially fatal heart rhythms","author":"U.S. Food and Drug Administration","year":"2013","unstructured":"U.S. Food and Drug Administration. 2013. Azithromycin (Zithromax or Zmax): drug safety communication\u2014risk of potentially fatal heart rhythms. U.S. Food and Drug Administration, Washington, DC. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm343350.htm."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00017-7"},{"key":"e_1_3_2_11_2","volume-title":"Abstr 26th Eur Congr Clin Microbiol Infect Dis","author":"Jamieson BD","year":"2016","unstructured":"Jamieson BD, Rewerska B, Tanaseanu CM, Vucinic-Mihailovic V, Taylor D, Sheets A, Keedy K, Oldach D, Fernandes P. 2016. SOLITAIRE-IV: a phase 3 IV to oral trial evaluating solithromycin in adults with community-acquired bacterial pneumonia, abstr P1338. Abstr 26th Eur Congr Clin Microbiol Infect Dis. European Society of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands."},{"key":"e_1_3_2_12_2","volume-title":"Abstr 53rd Intersci Conf Antimicrob Agents Chemother","author":"Hardy D","year":"2013","unstructured":"Hardy D, Vicino D, Fernandes P. 2013. Solithromycin (CEM-101) in vitro susceptibility of Bordetella pertussis, an emerging respiratory pathogen in the adult, abstr E-1187a. Abstr 53rd Intersci Conf Antimicrob Agents Chemother. American Society of Microbiology, Denver, CO."},{"key":"e_1_3_2_13_2","volume-title":"CLSI document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","volume-title":"CLSI document M7-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M7-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690992"},{"key":"e_1_3_2_16_2","volume-title":"Abstr 25th Eur Congr Clin Microbiol Infect Dis","author":"Darpo B","year":"2015","unstructured":"Darpo B, Philip S, Zhou M, Jamieson B, Fernandes P, Keedy K, Oldach D. 2015. Solithromycin, a 4th generation macrolide and the 1st fluoroketolide, does not prolong the QTc interval: results of a definitive QT study, abstr LBEV0081a. Abstr 25th Eur Congr Clin Microbiol Infect Dis. European Society of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01271-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01271-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:26:14Z","timestamp":1645475174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01271-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1128\/AAC.01271-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01271-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"2016-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}